Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I:Ab-(L-D)p Iwhere p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.半胱胺酸工程化之抗TENB2抗體係由用非交聯之反應性半胱胺酸胺基酸置換母體抗TENB2抗體之一或多個胺基酸工程化。提供該半胱胺酸工程化之抗TENB2抗體之設計、製備、篩選及選擇方法。半胱胺酸工程化之抗TENB2抗體(Ab)係經由連接基(L)與一或多個藥物部分(D)共軛以形成具有式I之半胱胺酸工程化之抗TENB2抗體-藥物共軛物：Ab-(L-D)p I其中p為1至4。揭示半胱胺酸工程化抗體藥物化合物及組合物之診斷及治療用途。
